Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Cesar Alvarez-Gonzalez"'
Autor:
Cesar Alvarez-Gonzalez, Richard Duggleby, Barbora Vagaska, Sergio Querol, Susana G Gomez, Patrizia Ferretti, Alejandro Madrigal
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67968 (2013)
Human umbilical cord blood (hUCB) has been proposed to contain not only haematopoietic stem cells, but also a rare pluripotent embryonic-like stem cell (ELSc) population that is negative for hematopoietic markers (Lin(-)CD45(-)) and expresses markers
Externí odkaz:
https://doaj.org/article/60aee6db13584d9e8a595596106db02b
Autor:
Ashok Adams, Cesar Alvarez-Gonzalez, Benjamin Turner, Klaus Schmierer, David Baker, Joela Mathews, Gavin Giovannoni
Publikováno v:
Annals of Clinical and Translational Neurology
Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT
Autor:
Sharmilee Gnanapavan, Özlem Yildiz, Stefania De Trane, Klaus Schmierer, Maria Espasandin, David Baker, Benjamin Turner, Cesar Alvarez-Gonzalez, Kimberley Allen-Philbey, Zhifeng Mao, Monica Marta, Tom Campion, Ashok Adams, Joela Mathews, Gavin Giovannoni
Publikováno v:
Multiple sclerosis and related disorders. 27
Background Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with progressive MS (pwPMS). Cladri
Publikováno v:
JAMA neurology. 74(8)
Importance Alemtuzumab, a CD52-depleting monoclonal antibody, effectively inhibits relapsing multiple sclerosis (MS) but is associated with a high incidence of secondary B-cell autoimmunities that limit use. These effects may be avoided through contr
Autor:
Maria Schroeder-Castagno, Alba Del Rio-Serrato, Andreas Wilhelm, Silvina Romero-Suárez, Patrick Schindler, Cesar Alvarez-González, Ankelien-Solveig Duchow, Judith Bellmann-Strobl, Klemens Ruprecht, Maria Hastermann, Gerald Grütz, Brigitte Wildemann, Sven Jarius, Tanja Schmitz-Hübsch, Friedemann Paul, Carmen Infante-Duarte
Publikováno v:
Journal of Neuroinflammation, Vol 19, Iss 1, Pp 1-17 (2022)
Abstract Background In neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neutrophils are found in CNS lesions. We previously demonstrated that NMOSD neutrophils show functiona
Externí odkaz:
https://doaj.org/article/db49c69e83c54a4a9442b01f0b920841
Autor:
Monica Marta, Gavin Giovannoni, Klaus Schmierer, Gabriel T. Doctor, David Baker, Cesar Alvarez-Gonzalez, Özlem Yildiz, Christo Albor, Derek Soon, Joela Mathews, Benjamin Turner, Stefania De Trane, Zhifeng Mao, George Pepper
Publikováno v:
Multiple Sclerosis Journal-Experimental, Translational and Clinical
Background A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective The objective of this comme
Autor:
Benjamin Turner, Gavin Giovannoni, Cesar Alvarez-Gonzalez, David Baker, Sharmilee Gnanapavan, Kimberley Allen-Philbey, Klaus Schmierer, Zhifeng Mao, Monica Marta, Joela Mathews
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 88:A47.4-A48
Background Evidence suggests cladribine is an effective, safe and convenient disease modifying therapy (DMT) for people with multiple sclerosis (pwMS). Objective To report our clinical experience using cladribine in pwMS using a dosing scheme adapted
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 88:A52.1-A52
Background The use of alemtuzumab in people with relapsing MS (pwRMS) is limited by the high risk of secondary B cell autoimmunity (SAI). Data describing the effect of alemtuzumab on lymphocyte subsets collected during the phase III trials has never
Autor:
Lukasz Zalewski, Klaus Schmierer, David Baker, Christo Albor, Samuel S. Herrod, Cesar Alvarez-Gonzalez
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation
Objective:To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies.Methods:The regulatory sub
Autor:
Patrizia Ferretti, Sergio Querol, Alejandro Madrigal, Cesar Alvarez-Gonzalez, Susana Gómez, Richard Duggleby, Barbora Vagaska
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67968 (2013)
PLoS ONE
PLoS ONE
Human umbilical cord blood (hUCB) has been proposed to contain not only haematopoietic stem cells, but also a rare pluripotent embryonic-like stem cell (ELSc) population that is negative for hematopoietic markers (Lin(-)CD45(-)) and expresses markers